SCHEMBL4522600

SCHEMBL4522600

Ic1ccc(N2CCCC(N3CCCC3)C2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.47
HRH3 Q9Y5N1 2/20 0.47
MAP4K4 O95819 2/20 0.45
NMT1 P30419 1/20 0.42
ADRA1A P35348 2/20 0.42
HRH4 Q9H3N8 2/20 0.42
ROCK2 O75116 3/20 0.41
ROCK1 Q13464 3/20 0.41
CDC42BPA Q5VT25 3/20 0.41
CDC42BPB Q9Y5S2 3/20 0.41
EGLN2 Q96KS0 1/20 0.40
MAPT P10636 2/20 0.36
UBE2T Q9NPD8 1/20 0.36
L3MBTL3 Q96JM7 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4517650 0.93 HDAC1 (0.46) HDAC1HRH3MAP4K4NMT1ADRA1A
SCHEMBL2324509 0.83 HRH3 (0.47) HDAC1HRH3MAP4K4NMT1ADRA1A
SCHEMBL24371998 0.79 ADRA1A (0.52) MAP4K4ADRA1AMAPTALDH1A1NPSR1
SCHEMBL1432869 0.79 MAPT (0.51) MAPTUBE2TALDH1A1LMNAALOX12
SCHEMBL1432610 0.78 MAPT (0.53) MAPTUBE2TALDH1A1LMNAALOX12
SCHEMBL30294197 0.77 MAP4K4 (0.51) HDAC1HRH3MAP4K4NMT1ADRA1A
SCHEMBL8281725 0.77 MAP4K4 (0.51) HDAC1HRH3MAP4K4NMT1ADRA1A
SCHEMBL23263993 0.77 MAP4K4 (0.51) HDAC1HRH3MAP4K4NMT1ADRA1A
SCHEMBL3564137 0.77 HTR1A (0.34) HDAC1HRH3NMT1ADRA1AHRH4
SCHEMBL1779679 0.75 HRH3 (0.45) HDAC1HRH3MAP4K4NMT1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8618132-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2013-12-31 US disclosed
EP-1558578-B1 NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA (DE) 2013-03-13 EP disclosed
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-03-12 US disclosed
US-7452911-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-11-18 US disclosed
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS MCHR1, MCHR2, GPR119 HDAC1 2996/4885HRH3 153/4885MAP4K4 3424/4885
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, MCHR2, NPY1R HDAC1 3190/4885HRH3 186/4885MAP4K4 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.